Search results
Showing 7501 to 7550 of 8236 results
Ventripoint Medical System Plus for measuring heart volume and function (MIB310)
February 2023: The medtech innovation briefing on Ventripoint Medical System Plus for measuring heart volume and function has been withdrawn as the company have withdrawn from the process.
Dapagliflozin with insulin for treating type 1 diabetes (TA597)
In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.
This guidance has been updated and replaced by NICE technology appraisal guidance 1054.
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
This guidance has been updated and replaced by NICE technology appraisal guidance 1018.
This guidance has been updated and replaced by NICE technology appraisal guidance 1043.
The MAGEC system for spinal lengthening in children with scoliosis (MTG18)
August 2024: Following the lifting on the UK suspension of MAGEC system (modified MAGEC X system), NICE's prioritisation board will be reviewing the guidance that was withdrawn in April 2020. We will update this page once a decision is made.
In February 2023, NICE withdrew this guidance following a review. The original guidance published in 2013 and recommended the use of WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension. However the guidance review in 2022 recommended it be withdrawn because it was determined that: The existing medical technologies guidance was considered along with other interventions in the update of NICE's guideline on atrial fibrillation. See evidence review A and evidence review B providing the best advice to the NHS about its use. As evident in NICE's guideline on atrial fibrillation, the evidence base and experts’ advice, the landscape for opportunistically detecting atrial fibrillation in primary care has changed significantly since the original guidance, with a wider range of devices for detecting atrial fibrillation now available.
January 2025: This quality standard has been stood down. Quality statements on maternal and child nutrition can be found in the NICE quality standards on antenatal care and postnatal care.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101.
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101.
The recommendations in this guideline on weight management during pregnancy have been updated and replaced by NICE's guideline on maternal and child nutrition (NG247). The recommendations on weight management before and after pregnancy have been updated and replaced by NICE’s guideline on overweight and obesity management (NG246).
Four commonly used methods to increase physical activity (PH2)
This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41 Physical activity: brief advice for adults in primary care (2013) PH44 Exercise referral schemes to promote physical activity (2014) PH54
This evidence summary has been withdrawn because licensed products are now available.
Discontinued Reference number: GID-TA10033
Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]
Discontinued Reference number: GID-TA10045
Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]
Discontinued Reference number: GID-TA10047
Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]
Discontinued Reference number: GID-TA10065
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066
Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746]
Discontinued Reference number: GID-TA10070
Melanoma (advanced, unresectable, metastatic, NRAS mutation positive) - binimetinib [ID833]
Discontinued Reference number: GID-TA10074
Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]
Discontinued Reference number: GID-TA10081
Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]
Discontinued Reference number: GID-TA10087
Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]
Discontinued Reference number: GID-TA10088
Biotin for treating primary and secondary progressive multiple sclerosis [ID919]
Discontinued Reference number: GID-TA10099
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued Reference number: GID-TA10105
Discontinued Reference number: GID-TA10109
Discontinued Reference number: GID-TA10110
Discontinued Reference number: GID-TA10126
Discontinued Reference number: GID-TA10133
Discontinued Reference number: GID-TA10134
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
Discontinued Reference number: GID-TA10138
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
Discontinued Reference number: GID-TA10140
Discontinued Reference number: GID-TA10144
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
Discontinued Reference number: GID-TA10148
Discontinued Reference number: GID-TA10149
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]
Discontinued Reference number: GID-TA10151
Discontinued Reference number: GID-TA10154
Discontinued Reference number: GID-TA10155
Masitinib for treating amyotrophic lateral sclerosis [ID967]
Discontinued Reference number: GID-TA10157
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
Discontinued Reference number: GID-TA10158
Discontinued Reference number: GID-TA10159
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
Discontinued Reference number: GID-TA10166
Discontinued Reference number: GID-TA10168
Discontinued Reference number: GID-TA10171
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Discontinued Reference number: GID-TA10177
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)
Discontinued Reference number: GID-TA10179
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Discontinued Reference number: GID-TA10180
NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655]
Discontinued Reference number: GID-TA10183